Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Care Specialists program Help your members on high-cost clinical drugs Insert Link Help members and their prescribers make better decisions about medicines through this clinical intelligence hub...

Reimagine your pharmacy benefit partner Get expert insights Go Somewhere Save, Simplify, Support™ Biologic drugs are transforming lives for the better, yet often at a substantial cost. Biosimilars,...

Cover image Specialty insights to watch Prime Therapeutics /summer-2026-prime-therapeutics-report The Summer 2026 Prime Therapeutics Report delivers practical insights on the therapies, trends and...

research 10 research posters presented by Prime at AMCP Nexus 2024 Studies include Prime’s GLP-1 obesity research, health equity, and real world case studies Evaluating the 10-Year Impact of an...

Oncology Insights Oncology Case Management and Navigation: How do they differ? Caring for and treating a patient with cancer is complex. Many patients struggle to coordinate therapy, manage...

50M Footnotes As many as 50M people in the United States have an autoimmune disease, making it the third most prevalent disease category, surpassed only by cancer and heart disease.2 Unlock...

Weight loss Support and empower weight loss in a healthy, manageable and sustainable way with customized paths for each member. Medication management Improve drug adherence or reduce the number of...

Flexible, cost-effective, strategic partnership Specialty drugs have changed the pharmacy landscape over the past decade and now represent more than half of total drug spend. Having a strong...

High Cost Therapy Profile Eyebrow High-Cost Therapy Profile: February Detailed information about Marnetegragene autotemcel Intravenous (IV) Gene Therapy/Immunology Marnetegragene autotemcel...